Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sevuparin failed for acute VOC in sickle cell, but may have preventive potential

Publish date:: January 21, 2020

Key clinical point: The novel nonanticoagulant heparinoid drug sevuparin failed to resolve acute vaso-occlusive crisis in patients with SCD but may have a role for preventing VOC.

Major finding: Time to VOC resolution was similar at about 168 hours in the treatment and placebo arms (intention to treat hazard ratio, 0.89).

Study details: A randomized, placebo-controlled, double-blind phase 2 study of 147 patients.

Disclosures: Dr. Biemond reported research funding from Sanquin and honoraria from Novartis and GBT.

Citation:

Biemond BJ et al. ASH 2019, Abstract 614.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Anemia

Emotions, worse attention linked to pain-related health care use SCD,

Oxidatative stress-related genetic variant tied to stroke risk in sickle cell patients,

Genetic variants may predict stroke in some adult SCD populations,

Severe COVID-19 may lower hemoglobin levels,

Low plasma sodium levels can predict complications in acute painful episodes of SCD,